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Abstract
Background: There is increasing interest in estimating the broader benefits of public health interventions beyond
those captured in traditional cost-utility analyses. Cost-benefit analysis (CBA) in principle offers a way to capture
such benefits, but a wide variety of methods have been used to monetise benefits in CBAs.
Methods: To understand the implications of different CBA approaches for capturing and monetising benefits and
their potential impact on public health decision-making, we conducted a CBA of human papillomavirus (HPV)
vaccination in the United Kingdom using eight methods for monetising health and economic benefits, valuing
productivity loss using either (1) the human capital or (2) the friction cost method, including the value of unpaid
work in (3) human capital or (4) friction cost approaches, (5) adjusting for hard-to-fill vacancies in the labour market,
(6) using the value of a statistical life, (7) monetising quality-adjusted life years and (8) including both productivity
losses and monetised quality-adjusted life years. A previously described transmission dynamic model was used to
project the impact of vaccination on cervical cancer outcomes. Probabilistic sensitivity analysis was conducted to
capture uncertainty in epidemiologic and economic parameters.
Results: Total benefits of vaccination varied by more than 20-fold (£0.6–12.4 billion) across the approaches. The
threshold vaccine cost (maximum vaccine cost at which HPV vaccination has a benefit-to-cost ratio above one)
ranged from £69 (95% CI £56–£84) to £1417 (£1291–£1541).
Conclusions: Applying different approaches to monetise benefits in CBA can lead to widely varying outcomes
on public health interventions such as vaccination. Use of CBA to inform priority setting in public health will
require greater convergence around appropriate methodology to achieve consistency and comparability
across different studies.
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Background
Health economic evaluations are used to inform medical
procurement and reimbursement decisions by public
and private healthcare providers. The most popular form
of health economic evaluation is cost-effectiveness
analysis (CEA), which often presents the ratio of the in-
cremental cost of an intervention (from the perspective
of either the healthcare provider or society) to the incre-
mental health benefits of an intervention. A review con-
ducted for the Bill & Melinda Gates Foundation of
health economic evaluations of interventions related to
malaria, tuberculosis, HIV/AIDS and vaccination in low-
and middle-income countries found that, of 204 studies
published in 2000–2013, 202 (99%) were CEAs [1].
Economic evaluations of large public health interventions
such as new vaccination programmes attract particularly
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intense debates because of the high absolute costs (and po-
tentially large benefits) involved [2]. A major focus of such
debates has been about whether current economic evalu-
ation techniques capture the full scope and value of these
public health programmes. For instance, several reviews
have found that vaccines may have broad, long-term
societal consequences that are not always captured in CEAs
[3, 4], although many of these benefits can, in principle, be
monetised and included in CEA based on a broader societal
perspective as recommended by the US Second Panel on
Cost-Effectiveness in Health and Medicine [5, 6]. Such
broader, non-health benefits of an intervention include
effects on future productivity and consumption, social ser-
vices, educational achievement and other societal impacts.
Several economists have instead proposed the use of
cost-benefit analysis (CBA) [7, 8]. The term CBA is often
informally used to refer to any analysis used in
decision-making that compares the expected costs and
benefits (both in monetary terms) of an investment. In
principle, to be regarded as complete, a CBA should
capture all benefits due to an intervention, valuing them
either at their market value or at the level of consump-
tion that individuals are willing to forego to obtain them.
Hence, it has its conceptual roots in welfare economics,
which quantifies social welfare in terms of individuals’
willingness-to-pay (WTP) to increase welfare. By using a
consistent, directly comparable metric to value all out-
comes, CBA allows comparison with non-health inter-
ventions. A recent analysis estimated that the return on
investment (a form of economic analysis that uses the
same economic assumptions as CBA) for vaccines in
low- and middle-income countries was comparable or
superior to that for non-health interventions such as
road safety [3].
The methodology for CEA has been well established,
with the perspective or range of costs admissible in a
CEA usually prescribed by ‘reference cases’ produced by
particular health authorities. In CEAs, the perspective
on costs can be narrow (costs and cost offsets falling to
healthcare providers alone, as recommended by the Na-
tional Institute for Health and Care Excellence (NICE)
in the UK) [9] or broad (all costs and cost offsets falling
on society, as recommended by the World Health
Organization (WHO)) [10]. NICE’s recommendation to
take a narrow perspective when estimating costs is rea-
sonable given that its evaluations are intended to pro-
mote the most efficient use of available resources
allocated to the NHS (or publicly funded health sectors)
in particular [11]. Conversely, the WHO Guide to
Cost-Effectiveness Analysis [10] explicitly recommended
all costs and health effects to be valued from the societal
perspective, because there are always opportunity costs
in every decision we make, such that all costs and re-
sources used for a chosen health intervention (regardless
of who paid them) could have been used for other pur-
poses in society, including non-health consumption. The
guide further argued that the so-called ‘decision-maker’s
approach’ taking such a narrow perspective is not consist-
ent with WHO’s concern that governments should strive
to maximise not only the overall health but also wellbeing
of societies. The Second Panel on Cost-Effectiveness in
Health and Medicine, composed of experts and leaders in
the field of health economics, has also provided two refer-
ence cases for healthcare sector and societal perspectives,
respectively, in their recent report. The Panel recom-
mended that CEAs are undertaken based on both per-
spectives to improve the quality and comparability of
CEAs [5].
Each of these approaches also affects the threshold by
which an option with a particular cost-effectiveness ratio
is deemed cost-effective. The CEA threshold is often de-
termined based on one of the following: (1) the oppor-
tunity cost of new spending at the margin of a budget
limit, (2) a multiple of GDP per capita, usually based on
human capital arguments (although they have also been
justified based on WTP) or (3) preference elicitation
(based on WTP) [12]. Using a decision-maker’s perspec-
tive and assuming that the decision-maker has control
over a budget with the objective of maximising health,
the threshold should arguably be set based on the oppor-
tunity cost of new spending at the margin of the
decision-maker’s budget. From a societal perspective, the
threshold should arguably instead be set based on either
the human capital value of improved health, or by pref-
erence elicitation (based on WTP) of societal willingness
to improve health.
In contrast, there is less detail around CBA method-
ology in health. While there exists guidance on conduct-
ing CBAs for government policies [13–15], it generally is
not as precise as ‘reference cases’ available for CEAs that
specify the exact economic assumptions to be used in
pharmacoeconomic evaluations. This is likely because
CBA has not been used as extensively as CEA for
informing decisions on specific healthcare resource allo-
cation. While CBA is used to evaluate a broader range
of public sector initiatives across multiple sectors, CEA
guidelines are generally used in the health sector only.
Given the increasing interest in using CBA to evaluate
the value of vaccinations and other major public health
programmes (as in part evidenced by the Bill & Melinda
Gates Foundation’s recent efforts to develop a reference
case for CBA), it is important to understand the implica-
tions of different approaches for capturing and monetis-
ing benefits. To this effect, we conducted a CBA of
human papillomavirus (HPV) vaccination as a case
study. HPV vaccination is a major public health invest-
ment that has been the topic of numerous CEAs with a
total of more than 60 studies identified across a number
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of systematic reviews [16–18]. Indeed, vaccination in
general has been subject to numerous studies assessing
costs and benefits based on various monetisation
methods [3, 19–22]. For the current study, we applied
eight different approaches to monetise benefits of HPV
vaccination and compared the results.
Methods
We conducted a CBA of HPV vaccination in the UK.
HPV is the aetiological agent of a number of cancers and
other diseases such as anogenital warts. Cervical cancer
has the highest global burden among the HPV-related
fraction of these cancers [23]. In particular, around 70% of
cervical cancers are caused by HPV-16 and HPV-18. We
have chosen this example as a large public health invest-
ment with a well-established model of HPV vaccine im-
pact used for national decision-making, so that our focus
in this study could be on the methodology of CBA rather
than on the modelling of HPV epidemiology. For simpli-
city, we focus only on the value of vaccination in prevent-
ing cervical cancer due to HPV-16 and HPV-18.
The decision to introduce HPV vaccination in the UK
was informed by a CEA that incorporated an epidemio-
logical model of HPV transmission [24] to assess the im-
pact of routine female adolescent two-dose vaccination
on cervical cancer burden over a time horizon of
100 years. We adopted the same epidemiological model
but used it as input for CBA. We assumed that (1) vac-
cination is given annually to 12-year-old girls at 80%
coverage, with a catch-up campaign in the first year to
age 16, and that (2) the vaccine provides lifelong protec-
tion against HPV-16 and HPV-18 without cross protec-
tion against other HPV types. Costs and benefits were
discounted at 3.5% per annum. For the probability sensi-
tivity analysis, we used Latin hypercube sampling to gen-
erate 1000 scenarios that encompass the uncertainties in
epidemiologic and economic parameters.
The outcome in our CBA was threshold vaccine cost
(TVC), which we defined as the maximum vaccine cost
per person (including the administration cost) at which
HPV vaccination has a benefit-to-cost ratio above one (i.e.
the vaccination programme is cost-beneficial) (Additional
file 1). The direct benefits of vaccination included all med-
ical cost avoided due to reduced screening for and treat-
ment of cervical cancer and pre-cancerous lesions
(Additional file 2: Table S1).
We applied two conceptually different approaches to
monetise benefits (lost production and WTP) to exam-
ine the impact of varying methods on the results. Esti-
mates of WTP were derived from stated or revealed
preference studies while lost production were measured
using the human capital and friction cost methods as
summarised in Table 1.
Lost production: Conventional production-based
approaches
While conventional CBA generally assumes that individ-
uals are the best judges of their own welfare (i.e. con-
sumer sovereignty) and that monetary values should
reflect individual willingness to exchange consumption
for the outcomes of concern (e.g. [25], p. 30), lost pro-
duction has also been commonly used in the CBA litera-
ture to value health [26–31]. Under these approaches,
productivity loss averted due to reduction in morbidity
and mortality were incorporated as indirect benefits of
vaccination in terms of the wider economic effects of
health as human capital (rather than its intrinsic value).
We considered the two most commonly used
production-based approaches, namely the human capital
(HC) and friction cost (FC) methods. From the perspec-
tive of affected individuals, the HC method assumes that
production loss incurred by sick or deceased workers is
irreplaceable. The duration of productivity loss for a sick
worker was therefore assumed to be the same as the en-
tire duration of disease treatment, whereas productivity
loss due to premature death was estimated by assuming
an average retirement age of 65. Specifically, production
loss was measured with a cumulative sum of income lost
over the duration of illness (morbidity) and the number
of years lost due to premature death (mortality) using
age-specific employment rates and mean personal in-
comes retrieved from the UK Office for National Statis-
tics [32, 33].
In contrast, the FC method takes the employer per-
spective and assumes that there always exists some level
of involuntary unemployment and hence a sick or de-
ceased worker is replaceable by an otherwise un-
employed worker [34]. As such, the FC method only
accounts for productivity loss during the friction period,
which is defined as the time between the first day of ab-
sence of a sick or deceased worker and the last day of
training for a replaced worker. According to the 2015
UK Recruitment Trends Report [35] based on responses
from major UK recruitment agencies, the average time
to fill a vacancy (i.e. time between announcing a job and
finding a successful applicant) ranged from 6 to 44 days
in 2014. The average time in training for a new em-
ployee of 6.8 days was derived from the UK Employer
Skills Survey 2015 [36]. As the friction period largely de-
pends on the type of job (e.g. longer friction period for
jobs requiring higher-level knowledge and skills) and
economic or labour market conditions, it was difficult to
find all the necessary data needed to estimate the fric-
tion period. We assumed that the sum of (1) the time
period between the start of absence by a sick employee
and the first day of job announcement and (2) the time
period between the acceptance of job offer and the first
day of training of a new employee to be approximately 3
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to 5 weeks in total based on Koopmanschap’s study [34].
The friction period in the UK was estimated to be ap-
proximately 34 to 86 days. In addition to productivity
loss incurred over the friction period, we considered
additional administrative costs related to hiring (£2610)
[36] and training (£5433) [37] a new worker for all mor-
tality and long-term morbidity cases (i.e. treatment
time > friction period).
The conventional production-based approaches ac-
count for productivity loss from individuals with the
paid jobs only and thus disregard homemakers who
comprise a substantial proportion of cervical cancer
cases (mean age 45, interquartile range 27–59) [38]. As
indicated in one of WHO’s guidelines on CBA, the eco-
nomic value of unpaid work, such as homemaking and
caring, is undervalued using this approach [39]. As such,
we also considered modified versions of the conven-
tional production-based methods (HC-M and FC-M) in
which paid labour and homemakers within the same age
group were assumed to have the same economic prod-
uctivity. The assumption is in line with the UK’s recent
effort in recognising the value of unpaid work at home
and its contribution to the economy, by providing it with
a monetary value equivalent to the average wages of
those who are paid to do those tasks [40]. The propor-
tion of homemakers in each age group was approxi-
mated based on the Office for National Statistics
employment statistics [13].
Lost production: a new production-based approach
The conventional production-based approach has the ad-
vantage that it uses relatively objective and quantifiable
measures (e.g. wage rates) compared to a WTP-based ap-
proach. However, the theoretical framework of neither the
HC nor the FC method is completely sound, because (1)
the HC method’s underlying assumption of full employ-
ment is often considered unrealistic and (2) the friction
period of the FC method largely varies across occupations,
times and countries. In order to address both issues, we
examined how easily job vacancies could actually be filled
within the ‘normal’ friction period in the current UK
labour market.
We considered a new approach for estimating prod-
uctivity loss by interpolating between the HC and FC
Table 1 Overview of cost-benefit analysis (CBA) approaches to monetise benefits
Method Rationale Major limitations and uncertainties How we accounted for methodological
uncertainties
Human capital ▪ Individual perspective
▪ Indirect benefits are productivity
losses avoided by prevented or
reduced morbidity and mortality
▪ Productivity losses are valued by
individual’s cumulative income over
the entire time absent from work
▪ Considers productivity loss incurred
only by economically active individuals
▪ Leads to biased decisions in favour of
high-income earners and economically
active individuals
▪ Sensitivity analysis was conducted to include
homemakers in the calculation of productivity
loss averted
Friction cost ▪ Employer perspective
▪ Indirect benefits are productivity
losses avoided by prevented or
reduced morbidity and mortality
▪ Productivity losses are valued by
individual’s gross earnings over the
friction period
▪ Assumes there always exists some
level of involuntary unemployment
▪ The sick/deceased worker is
replaced by another worker who
otherwise would have remained
unemployed
▪ Disease- and job-specific data needed
for estimating the friction period are
often unavailable
▪ Considers productivity loss incurred
only by economically active individuals
▪ Leads to biased decisions in favour of
high-income earners and economically
active individuals
▪ Sensitivity analysis was conducted to vary
friction period – 55, 69 and 90 days – to
account for uncertainties regarding the vacancy
duration
▪ Sensitivity analysis was conducted to include
homemakers in the calculation of productivity
loss averted
Value of a
statistical life
(VSL): Revealed
Preference
▪ Individuals implicitly reveal how
much they value mortality risk
reduction in real markets (e.g. wage-
risk trade-offs)
▪ VSL is derived from observed
behaviours
▪ Focus is mostly on job-related risks
among working-age population, which
largely result from injuries rather than
illnesses
▪ A range of VSL estimates, including a VSL for
cancer after adjusting for a 10-year latency
period was used
VSL: Stated
Preference
▪ Use contingent valuation with
hypothetical scenario (i.e. surveys) to
derive VSL
▪ Extra effort may be required to
encourage survey participants for valid
responses
▪ A range of VSL estimates, including one from
a willingness-to-pay (WTP) study done in cer-
vical cancer patients was used
Monetisation of
quality adjusted
life years (QALYs)
(QM)
▪ QALY captures a broad range of
health benefits
▪ QALY can be monetised by
multiplying the WTP with gains in
QALYs
▪ Individuals cannot be expected to
have a constant rate of substitution
between QALYs and wealth
▪ Our QM approach with a £23,000/QALY WTP
is analogous to NICE’s cost-effectiveness refer-
ence case, which has a cost-effectiveness
threshold of £20,000–£30,000/QALY [9]
Park et al. BMC Medicine  (2018) 16:139 Page 4 of 11
methods (HC/FC). Under this approach, productivity
loss was a weighted average of that under the two
methods where the weight for HC corresponded to the
proportion of jobs that are unlikely to be filled within
the friction period in the current labour market. We es-
timated this weight based on recent statistics on ‘hard--
to-fill vacancies’ (HtFV) from the UK Commission’s
Employer Skills Survey 2015 (Additional file 3: Table S2)
[36]. HtFV refer to vacancies that are difficult to fill due
to skill-related (e.g. lack of qualified applicants) or
non-skill-related reasons (e.g. low pay offered for the
post). It was noted that there is a major gender differ-
ence in occupational employment in the UK [41], with
women historically dominating employment in jobs such
as leisure and caring while men dominating in construc-
tion industry, for example. To take into account the gen-
der difference in occupational employment and largely
varying proportions of HtFV by industry sector [36], we
calculated the weighted proportion of HtFV for women to
be used in the analysis. We compiled two recent UK em-
ployment statistics that provide (1) the distribution of fe-
male workforce [42] and (2) the proportion of HtFV in 13
industry sectors categorised according to the Standard In-
dustrial Classification [36]. The distribution of females in
the workforce largely varied by industry sector, ranging
from 0.6% in agriculture to 22% in health and social work,
while the proportion of HtFV (regardless of gender)
ranged from 23% in education to 43% in construction.
WTP: the value of a statistical life (VSL) approach
Under this approach, the monetary values of both pecu-
niary (e.g. avoided medical expenses) and non-pecuniary
(e.g. pain and suffering associated with the disease) ben-
efits are presumed to be encapsulated by VSL estimates
given that individuals’ WTP takes into account the im-
pact of mortality risk reductions on their wellbeing in
every aspect. The VSL estimates are used to value mor-
tality risk reductions and obtained via (1) revealed pref-
erences (VSL-RP) based on labour-market or hedonic
wage studies; or (2) stated preferences (VSL-SP) based
on contingent valuation studies [8]. While the VSL gen-
erally does not address morbidity associated with
non-fatal cases, it has been suggested that VSL-RP may
as well include the value of the associated morbidity risk
though it is likely to be minimal (6–25%) compared to
the value of the fatality risk [43]. As for the VSL-SP,
there has been mixed evidence regarding the morbidity
premium (or cancer premium) to take into account the
effects of morbidity associated with the fatality in the
VSL estimate [44–46]. This highlights a key advantage of
the VSL approach over the HC or FC methods that do
not take into account the intrinsic value of health gains.
We considered seven different VSL estimates derived
from three individual studies (labelled as ‘Lang’, ’Viscusi’
and ‘Gayer 1–2’ in Fig. 1) and three normative national
and international guidance (‘UKHSE’, ‘USDoT’ and
‘OECD’) (Additional file 4: Table S3). For VSL-RP, we se-
lected (1) a VSL estimate currently in use by the US De-
partment of Transportation (‘USDoT’) [47], which is
very similar to that adopted by the US Department of
Health and Human Services [14] and the US Environ-
mental Protection Agency [15], as well as the estimated
means from a meta-regression analysis, which adjusted
for publication bias [48], and (2) a range of VSL for can-
cer risk reduction estimated based on hedonic housing
prices in the US (‘Gayer 1–2’) [49]. For VSL-SP, we se-
lected VSL estimates from (1) a WTP study conducted
among cervical cancer patients in Taiwan (‘Lang’) [50],
(2) a recent systematic review of VSL focusing on a ‘can-
cer premium’ (‘Viscusi’) [45], (3) recommendation of the
UK Health and Safety Executive (‘UKHSE’) [13], and (4)
OECD guidelines for EU-27 countries (‘OECD’) [44]. All
VSL estimates were converted to the current UK cur-
rency based on the OECD guideline [44]. To convert
VSL values varying across countries and over time to the
UK 2015 value, we used the benefit transfer method with
income adjustments. For example, to approximate VSL
used by the US Department of Transportation, we used
purchasing power parity (PPP)-adjusted GDP per capita
in the following equation:
VSLUK;2015 ¼ VSLUS;2015
PPP−adjusted GDP per capitaUK ;2015=PPP−adjusted per capitaUS;2015
 
:
Here, PPP-adjusted GDP per capita for both the UK and
the US were extracted from the World Bank [51]. To con-
vert the VSL (in USD) estimated from the above equation
to the UK currency, we used PPP-adjusted exchange rates
from OECD Statistics [52]. To update VSL values across dif-
ferent years (e.g. 2000 to 2015), we used the average Con-
sumer Price Index and Real Income in the UK as follows:
VSL2015 ¼ VSL2000
CPI2015=CPI2000ð Þ Real Incomes2014=15=Real Incomes1999=00
 
Data on Consumer Price Index and Real Incomes
across different years were available at the UK Office for
National Statistics website [53]. After the adjustment,
the selected VSL estimates ranged from £1.1 million to
£7.2 million. Each adjusted VSL estimate was then
multiplied by the projected number of cervical cancer
deaths prevented from vaccination.
WTP: the quality-adjusted life-year (QALY) monetisation
(QM) approach
Under this approach, the health outcome in conven-
tional cost-utility analyses, namely QALY, was monetised
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using individual WTP for an additional QALY gained.
Based on a study that assessed WTP for the respondent’s
own additional QALY gained (WTPsel) in the UK [54],
we applied £23,000 to the discounted QALY gained. Our
QM approach with a £23,000/QALY WTP is analogous
to NICE’s cost-effectiveness reference case, which has a
cost-effectiveness threshold of £20,000–£30,000/QALY
[9], although our approach is based on individual rather
than societal WTP arguments. Hence, it would be ex-
pected that the net present value of an intervention
using our QM approach would correspond to its net
monetary benefit evaluated using NICE’s reference case.
Integration of production-based and QM approaches
Under these approaches, productivity loss from
production-based approaches and monetised QALYs
gained were both included when estimating the eco-
nomic benefit of vaccination (e.g. HC/QM when HC is
integrated with QM) to capture both the intrinsic and
the instrumental value of better health. Such analyses
are analogous to cost-utility analyses using a societal
perspective.
Future deaths averted were discounted at 3.5% per
annum back to the reference year, i.e. the year in which
the vaccination programme is initiated. Subsequently,
the value attached to averted mortality was discounted fur-
ther, depending on the method used. For production-based
(HC and FC) and QM approaches, the productivity loss
and QALYs lost for each year of life lost due to premature
death was discounted back to the year of death. For the
VSL-based approaches (VSL-RP and VSL-SP), the same
value was ascribed to a prevented death regardless of the
age of the woman or the number of life years averted, as
has been standard practice for public policy analyses [55].
Results
Among all CBA methods considered, the WTP-based
approach using the VSL yielded the highest TVC esti-
mates. Specifically, the median TVC estimates ranged
from £206 (interquartile range: £187–£223) to £939
(£855–£1021) under VSL-SP and £734 (£669–£798) to
£1417 (£1291–£1541) under VSL-RP, which correspond
to approximately 78.6% and 541% of the TVC estimated
under the standard QM method (£262), respectively
(Fig. 1). When the QM approach was integrated with the
production-based approaches, the TVC estimates ranged
from £268 (£244–£293) with FC/QM to £373 (£345–
£407) with HC/QM and remained lower than that esti-
mated under the VSL method.
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Fig. 1 Direct and indirect benefits of two-dose HPV vaccination in the UK (top) and threshold vaccine cost (TVC) estimates (bottom) under
different cost-benefit analysis (CBA) approaches
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Under the production-based approach, the direct
benefit was £0.54 billion (£0.44 billion to £0.66 billion).
The mean UK female employment rate used to measure
the indirect benefits in terms of averted productivity loss
was 36.9% for those aged 16–19 and 64.7–77.6% for
those aged 20–64. The indirect benefits varied 9-fold
across different monetisation methods utilising the
production-based approach, at £33 million in FC, £37
million in FC-M, £946 million in HC, £1.1 billion in
HC-M, and £324 million in HC/FC (Fig. 1). Conse-
quently, the FC method resulted in the lowest TVC esti-
mate of £69 (£56–£84), which is only 26% of the TVC
estimated under the QM. When integrated with the QM
method, the total indirect benefits increased by nearly
53-fold (£1.7 billion) and 2-fold (£2.6 billion) for the FC
and HC methods, respectively. Similarly, with home-
makers (around 8.9%–13.9% across the different age
groups in 2015) included in the calculation of productiv-
ity loss under the modified production-based ap-
proaches, the TVC estimate increased by 1–2% (from
£56–£84 to £57–£85) and 8–10% (from £157–£195 to
£172–£211) under the FC and HC method, respectively
(Additional file 5: Table S4).
Point estimates and error bars indicate medians and
interquartile ranges across 1000 scenarios randomly gen-
erated. Benefits under the VSL approaches cannot be
decomposed into direct and indirect components. VSL
estimates used in Gayer–1 and –2 were derived from the
same study using different level of cancer risk [49].
The proportion of HtFV varied by industry sector, ran-
ging from 23% in education (in which 16% of women work)
to 43% in construction (in which fewer than 2% of women
work). Considering the gender difference and varying pro-
portions of HtFV across different establishments, we esti-
mated that the overall proportion of HtFV among the
female workforce in the UK was 31% (Additional file 3:
Table S2). That is, we estimated that 69% of all vacancies
would be filled with a replaced worker within the friction
period. The resulting TVC estimate was £101 (£88–£118)
under HC/FC, which was 56% lower and 11% higher than
that under HC and FC, respectively. Relative changes in
TVC were similar when homemakers were included in the
calculation of productivity loss.
We found that the economic benefits of vaccination
against HPV-16 and HPV-18 in the UK could vary by as
much as 20-fold depending on the method used to mon-
etise benefits. In particular, two-dose HPV vaccination in
the UK was found to be not cost-beneficial under the
HC approach and all FC-related approaches except when
integrated with QM.
Discussion
Our results suggest that using different approaches to
monetise benefits can lead to divergent conclusions about
the value of vaccination. Our TVC estimates for a vaccine
against cervical cancer in the UK ranged over an order of
magnitude (£69–£1417) depending on the method used to
value the benefits of cervical cancer prevention. The TVC
estimate was lowest (£69–£191) when benefits were val-
ued in terms of productivity loss averted due to ill health
and premature mortality, particularly if the friction cost
method was used, and highest (£206–£1417) when VSL
methodology was used. When an individual WTP for an
additional QALY gained was used instead, the TVC esti-
mates (£262–£373) were generally higher than that ob-
tained by valuing productivity gains but lower than that
obtained using VSL methods.
Our finding that measuring benefits based on WTP esti-
mates (e.g. the VSL and QM approaches) yields larger
benefit estimates than measuring benefits based on lost
production (e.g. HC and FC) is unsurprising – this is likely
because the former includes both financial (e.g. medical
expenses and losses in future earnings) and non-financial
(e.g. avoided pain and suffering) benefits of the interven-
tion, whereas the latter solely focuses on lost production
[56, 57]. The finding that the FC method yields much
smaller benefit estimates than the HC method is likewise
intuitive, because the FC method only takes into account
temporary losses during the friction period while the HC
method assumes lifetime losses during the entire period
affected by morbidity and mortality.
Each of the methods used has advantages and limitations.
Production-based approaches for valuing health gains have
been criticised for not being consistent with the theoretical
foundations of CBA in welfare economics, as they focus on
changes in productivity rather than measuring overall wel-
fare. Similarly, QALY-based approaches do not fit naturally
within the conceptual framework of welfare economics, be-
cause they measure changes in health rather than overall
welfare. The approach that most directly reflects the princi-
ples of welfare economics is to estimate the consumption
that affected individuals are willing to trade-off to avoid
morbidity or mortality [27, 58, 59].
Valuing benefits based on averted productivity loss has
the advantage of being based on an easily measurable
quantity (market income). However, for diseases such as
cancer, which tend to cause long-term work absences,
the difference in outcome between the production-based
approaches can be large. In our study, productivity loss
estimates under the HC approach were 29 times higher
than that under the FC approach. Similarly, Oliva et al.
[60] found that the annual productivity cost of mortality
due to cervical cancer in Spain was €21.7 million based
on HC and €0.39 million with FC (56-fold difference).
Advocates of the FC method argue that there is always
some level of involuntary unemployment, so the HC
method overestimates the societal cost of long-term ill-
ness or death by measuring the ‘potential’ productivity
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loss over the entire period of absenteeism beyond the
friction period [34]. The FC method purports to meas-
ure the ‘actual’ productivity loss to society from an em-
ployer’s perspective by considering the time and related
costs (e.g. hiring and training costs) needed to fully re-
store production levels with a replacement worker.
Both conventional production-based methods have been
criticised for valuing life purely in terms of marketable
productive capacity and not providing an explicit value for
the health gains themselves (i.e. ignoring the additional
value of avoided suffering, leisure time and unpaid labour)
[61]. The concern is that this may lead to prioritising in-
terventions that primarily benefit high-wage earners over
low-wage earners and those doing unpaid labour (e.g.
caregiving and housework). In our analysis, we have
accounted for unpaid labour by employing the modified
versions (namely HC-M and FC-M) and estimate that the
TVC for HPV vaccination increases by 22% with the HC
and 2% with the FC method if all females are included in
productivity loss calculations (data not shown here), ra-
ther than those in the paid labour force only. It should be
noted, however, that the market value approach that we
used measures unpaid household work based on the
population average wage, which differs from the conven-
tional method of valuing household based on the average
wage of a paid household worker or carer.
Measuring lost production by using wage rates raises a
number of methodological questions, including (1)
whether or not to assume full employment (we capture
this uncertainty by showing results using both HC, which
assumes full employment and competitive labour markets,
and FC, which does not make these assumptions), (2)
whether the economic value of lost productivity is best
captured by the employer perspective (so measured in
pre-tax wages including fringe benefits and indirect costs)
or employee perspective (so measured in post-tax wages),
and (3) how to capture labour market constraints on how
much work an individual does, since there may be re-
quirements to work a fixed number of hours [62]. For ex-
ample, Bockstael et al. [63] found that individuals who are
required to work a fixed number of hours valued the op-
portunity cost of time approximately 3.5-fold more than
the wage rate, whereas those with flexible working hours
valued it similarly to their wage rate.
We proposed an alternative production-based method
that may be used instead of established methods, as it
strikes a balance between the two approaches in terms of
assumptions about unemployment. Weighting the outputs
from the two methods according to the proportion of
HtFV should theoretically give estimates closer to the ac-
tual productivity loss due to ill-health.
An alternative approach is the VSL method. The VSL
reflects the marginal rate of substitution between money
(or income) and mortality risk and infers the value of
the consumption of market goods that individuals are
willing to forgo to achieve a reduced risk of premature
death [8]. Hence, VSL can be seen as a direct application
of the welfarist principle of consumer sovereignty. Con-
sistent with the conceptual framework for CBA, VSL esti-
mates are highly context specific. In practice, however,
researchers often rely on the averages across country pop-
ulations (or even extrapolations from other countries),
which can potentially cause under- or overestimations of
the result. Furthermore, there are few VSL estimates from
low- or middle-income countries. VSL estimates for can-
cer are particularly divergent, with debates around the ex-
istence and magnitude of a ‘cancer premium’ that inflates
the VSL for a cancer death in comparison to a death from
an acute fatality to incorporate the latency and morbidity
period of cancer. For instance, Viscusi et al. [45] suggested
the use of 1.21 for cancer premium, the US Environmental
Protection Agency, the European Commission and several
studies recommend a cancer premium of 1.5 [46, 64, 65],
and the UK’s Health and Safety Executive doubles the VSL
(or the value of preventing a statistical fatality) estimates
of accidental death to derive a VSL estimate for cancer
[13]. We understand that there are concerns about trans-
ferring VSL between countries with different healthcare
systems, income levels and cultural values that may affect
mortality risk valuation. Nevertheless, we have used VSL
estimates derived from other countries also for the follow-
ing reasons: (1) there is disagreement and inconsistency
with the use of a ‘cancer premium’ when applying a stand-
ard VSL to cancer studies and (2) there were few studies
reporting cancer-specific VSLs at the time of the study,
none of which was from the UK. To minimise such ef-
fects, we have adjusted for different income levels and
costs between the countries using the ‘unit transfer with
income adjustments’ method.
A third approach is to monetise individual WTP for an
additional QALY gained. It offers policymakers the flexi-
bility to incorporate additional units for the value of
non-health outcomes not captured in measures such as
QALYs, as well as to compare outcomes with non-health
interventions. In practice, monetised QALYs has been
used by government agencies such as the US Department
of Health and Human Services [14] and US Food and
Drug Administration for regulatory analyses [66]. How-
ever, there is still an on-going debate around the use of
monetised QALYs in healthcare decision-making among
health economists. During the meeting organised by the
US National Institutes of Health in 2010, for example, it
was argued that QALYs should not be monetised since
this approach lacks theoretical and empirical support [67].
It should also be noted that adding productivity costs to
monetised QALYs may lead to double counting, as there
remains uncertainty about whether productivity loss has
been fully captured in QALY measures [5, 6].
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Hence, a key challenge to using CBA for priority setting
around public health interventions is the great variety in
the way benefits can be monetised and the relative lack of
detail on normative guidance about the appropriate meth-
odology to use.
Conclusions
In principle, CBA offers the opportunity to capture many
benefits of public health interventions such as vaccination
that may not naturally fit into a CEA framework. Other ap-
proaches, such as cost-consequences analysis and multiple
criteria decision analysis, also admit a wider range of out-
comes, but do not offer a straightforward way to synthesise
multiple outcomes into a single measure. Wider use of
CBA to evaluate public health interventions will require
greater convergence around the appropriate methodology
to use in order to achieve consistency and comparability
across different studies. Ultimately, discussions around ap-
propriate methodology for CBA could help us better under-
stand what we actually value about health.
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